Omeros' Hail Mary throw for blood clot med application delayed at FDA

Rather than accepting a loss when the FDA rejected its stem-cell-associated blood clot med, Omeros took the road less traveled with an appeal, arguing that there's enough data to support the approval of narsoplimab. Now, that effort has likely been stalled until after August.